oestradiol
Phase 3Small molecule
oestradiol is one of 62 small molecule programs targeting Adenomyosis. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
269 competitors in Metastatic Prostate Cancer
#DrugCompanyPhaseTrials
1Xtandi
AstellasPhase 3
Taxotere
AAvyxa
Phase 3
Erleada
Johnson & JohnsonPhase 3
Nubeqa
BayerPhase 3
Jevtana
SanofiPhase 3
Zoladex
AstraZenecaPhase 3
Rayos
RRoxane Laboratories
Phase 3
Zometa
PfizerPhase 3
Prolia
AmgenPhase 3
Medrol
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Prostate Cancer1 trial
Adenomyosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oestradiol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Toulouse